Remove Pharma Companies Remove Pharmaceuticals Remove Research
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

article thumbnail

The High-Stakes Game of Pharma IP: Why Benchmarking Your Pipeline is Non-Negotiable

Drug Patent Watch

"The Pharmaceutical Industry's Best-Kept Secret: How Benchmarking Your Pipeline Can Be the Key to Unlocking Unprecedented Growth As the pharmaceutical landscape continues to evolve at breakneck speed, one thing remains constant: the importance of intellectual property (IP) in driving innovation and success.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target. With over 25 years of experience in biomedical research, Stephan has dedicated his career to the development of novel therapeutics addressing unmet medical needs.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Since Arvinas’ findings, another company, Kymera Therapeutics, showed that a protein-destroying medicine it developed may be able to stifle a drug target others have struggled to reach. For years, researchers struggled to develop an effective method for directing the E3 ligase. There’s a real burning desire to show more progress.”

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharma companies were the originators in only 28% of approvals[4].

article thumbnail

Tackling complex manufacturing challenges in modern drug development

Drug Target Review

Daniel Galbraith, Chief Scientific Officer at Solvias , brings extensive expertise in the pharmaceutical and biotechnology sectors. In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.